NCT04512027View on ClinicalTrials.gov

Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

September 19, 2020

Study Completion Date

October 16, 2020

Conditions
COVID-19
Interventions
OTHER

Prolectin-M; a (1-6)-alpha-D-Mannopyranose class

A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19

OTHER

Standard of Care

Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.

Trial Locations (1)

560099

Mazumdar Shaw Medical Centre, Bangalore

All Listed Sponsors
collaborator

Bioxytran Inc.

INDUSTRY

lead

Composite Interceptive Med Science

INDUSTRY

NCT04512027 - Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. | Biotech Hunter | Biotech Hunter